Metabolic ratios of four probes of CYP2D6 in Turkish subjects: A cross-over study

被引:15
作者
Bozkurt, A [1 ]
Basci, NE [1 ]
Isimer, A [1 ]
Sayal, A [1 ]
Kayaalp, SO [1 ]
机构
[1] GULHANE MIL MED ACAD,FAC MED,DEPT PHARMACOL,ANKARA,TURKEY
关键词
debrisoquine; sparteine; metoprolol; dextromethorphan; oxidation polymorphism; Turkish population;
D O I
10.1007/BF03189732
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The relationships among the metabolic ratios for the standard probe drugs of CYP2D6 activity, such as debrisoquine, sparteine, metoprolol. and dextromethorphan, were studied in 32 Turkish subjects. All subjects were randomly selected according to their phenotypes from a group of 111 Turkish subjects whose oxidation status had been tested for debrisoquine previously. All subjects were given a 10 mg debrisoquine tablet, a 100 mg sparteine tablet, a 100 mg.metoprolol tablet and a 20 mg dextromethorphan capsule orally with a wash-out period of at least 1 week between each probe administration. Metabolic ratios were calculated as percentage of dose excreted as parent drug/percentage of dose excreted as its hydroxymetabolite of parent drug in 0-8 h urine. Three poor metabolisers (PM) of debrisoquine were identified. They were also PMs of the other test probes and no misclassification by the 4 phenotyping methods was observed. All six correlations among the metabolic ratios of the 4 probe drugs assessed by Spearman's rank test were highly significant (P < 0.001). The present findings indicate that the oxidative metabolism of debrisoquine, sparteine, metoprolol and dextromethorphan is catalysed by the same cytochrome P450 in the Turkish subjects.
引用
收藏
页码:309 / 314
页数:6
相关论文
共 17 条
[1]   CORRELATION BETWEEN THE METABOLIC RATIOS OF DEBRISOQUINE AND METOPROLOL IN TURKISH SUBJECTS [J].
BASCI, NE ;
BOZKURT, A ;
ISIMER, A ;
KAYAALP, SO .
PHARMACOLOGY & TOXICOLOGY, 1994, 75 (01) :62-64
[2]   S-MEPHENYTOIN, SPARTEINE AND DEBRISOQUINE OXIDATION - GENETIC POLYMORPHISMS IN A TURKISH POPULATION [J].
BASCI, NE ;
BROSEN, K ;
BOZKURT, A ;
ISIMER, A ;
SAYAL, A ;
KAYAALP, SO .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 38 (05) :463-465
[3]   POLYMORPHIC DEBRISOQUIN METABOLISM IN A TURKISH POPULATION [J].
BOZKURT, A ;
BASCI, NE ;
ISIMER, A ;
SAYAL, A ;
KAYAALP, SO .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (04) :399-401
[4]   DETERMINATION OF DEBRISOQUINE AND 4-HYDROXYDEBRISOQUINE IN URINE BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH FLUORESCENCE DETECTION AFTER SOLID-PHASE EXTRACTION [J].
BOZKURT, A ;
BASCI, NE ;
ISIMER, A ;
KAYAALP, SO .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1993, 11 (08) :745-749
[5]   THE GENETIC-POLYMORPHISM OF DEBRISOQUINE SPARTEINE METABOLISM - CLINICAL ASPECTS [J].
EICHELBAUM, M ;
GROSS, AS .
PHARMACOLOGY & THERAPEUTICS, 1990, 46 (03) :377-394
[6]   POLYMORPHIC OXIDATION OF SPARTEINE AND DEBRISOQUINE - RELATED PHARMACOGENETIC ENTITIES [J].
EICHELBAUM, M ;
BERTILSSON, L ;
SAWE, J ;
ZEKORN, C .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1982, 31 (02) :184-186
[7]   A FAMILY AND POPULATION STUDY OF THE GENETIC-POLYMORPHISM OF DEBRISOQUINE OXIDATION IN A WHITE BRITISH-POPULATION [J].
EVANS, DAP ;
MAHGOUB, A ;
SLOAN, TP ;
IDLE, JR ;
SMITH, RL .
JOURNAL OF MEDICAL GENETICS, 1980, 17 (02) :102-105
[8]   CORRELATIONS AMONG THE METABOLIC RATIOS OF 3 TEST PROBES (METOPROLOL, DEBRISOQUINE AND SPARTEINE) FOR GENETICALLY-DETERMINED OXIDATION POLYMORPHISM IN A JAPANESE POPULATION [J].
HORAI, Y ;
TAGA, J ;
ISHIZAKI, T ;
ISHIKAWA, K .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 29 (01) :111-115
[9]   METOPROLOL AND DEBRISOQUIN METABOLISM IN NIGERIANS - LACK OF EVIDENCE FOR POLYMORPHIC OXIDATION [J].
IYUN, AO ;
LENNARD, MS ;
TUCKER, GT ;
WOODS, HF .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 40 (04) :387-394
[10]  
LAM YWF, 1993, THER DRUG MONIT, V15, P300